Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade

verfasst von: Yong Ding, Yucai Wang, Jun Chen, Yunsheng Hu, Zhuo Cao, Pengcheng Ren, Yong Zhang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma is the most common form of primary malignant bone tumor that mainly occurs in juvenile patients. The mechanisms of formation and development of osteosarcoma have been studied for a long time. Recently, more and more evidence showed that p21 plays important roles in regulating tumor growth. To study the effects of p21 on the chemosensitivity of human osteosarcoma U2OS cells to cisplatin and its relevant mechanisms, we stably transfect the pC-21-SN3 vector containing P21 to U2O3 cells (U2O3-p21), which was identified by RT-PCR and Western blot. The results showed that no p21 was expressed in U2OS and U2OS-vec cells, but it was highly expressed in U2O3-p21 cells at mRNA and protein levels. The growth of U2OS cells was almost not influenced by p21 alone. However, U2O3-p21 cells underwent more obvious apoptotic morphological changes than U2OS and U2OS-vec cells after being treated with cisplatin (5 μg) for 72 h. Besides, increased expression of cleaved caspase-3 and Bax/Bcl-2 ratio was observed in cisplatin-treated U2O3-p21 cells. These data clearly indicated that exogenous p21 gene transfection could enhance the cisplatin-induced cytotoxicity against human osteosarcoma U2OS cells, at least in part, by activating caspase-3 cascade and increasing Bax/Bcl-2 ratio.
Literatur
1.
Zurück zum Zitat Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805–16.PubMedCrossRef Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805–16.PubMedCrossRef
2.
Zurück zum Zitat Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76:1013–23.PubMedCrossRef Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76:1013–23.PubMedCrossRef
3.
Zurück zum Zitat Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem. 2001;276:42971–7.PubMedCrossRef Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem. 2001;276:42971–7.PubMedCrossRef
5.
Zurück zum Zitat Matsumoto T, Sowa Y, Ohtani-Fujita N, Tamaki T, Takenaka T, Kuribayashi K, et al. p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cancer Lett. 1998;129:61–8.PubMedCrossRef Matsumoto T, Sowa Y, Ohtani-Fujita N, Tamaki T, Takenaka T, Kuribayashi K, et al. p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cancer Lett. 1998;129:61–8.PubMedCrossRef
6.
Zurück zum Zitat Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med. 1996;213:138–49.PubMedCrossRef Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med. 1996;213:138–49.PubMedCrossRef
8.
Zurück zum Zitat Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001;61:6234–8.PubMed Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001;61:6234–8.PubMed
9.
10.
Zurück zum Zitat Zhang Y, Sturgis EM, Zafereo ME, Wei Q, Li G. p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer. 2011;117:1227–35.PubMedCentralPubMedCrossRef Zhang Y, Sturgis EM, Zafereo ME, Wei Q, Li G. p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer. 2011;117:1227–35.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRef Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.PubMedCrossRef Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.PubMedCrossRef
13.
Zurück zum Zitat Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y, Ashihara T. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res. 2001;21:317–20.PubMed Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y, Ashihara T. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res. 2001;21:317–20.PubMed
14.
Zurück zum Zitat Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K, Mankin HJ. Experimental models for the study of drug resistance in osteosarcoma: p-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg. 1996;78A:366–75. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K, Mankin HJ. Experimental models for the study of drug resistance in osteosarcoma: p-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg. 1996;78A:366–75.
15.
Zurück zum Zitat Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer. 2012;51:696–706.PubMedCrossRef Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer. 2012;51:696–706.PubMedCrossRef
16.
Zurück zum Zitat Zhong GX, Liu AL, Lin JH. Detection of femtomolar level osteosarcoma-related gene via a chronocoulometric DNA biosensor based on nanostructure gold electrode. Int J Nanomedicine. 2012;7:527–36.PubMedCentralPubMedCrossRef Zhong GX, Liu AL, Lin JH. Detection of femtomolar level osteosarcoma-related gene via a chronocoulometric DNA biosensor based on nanostructure gold electrode. Int J Nanomedicine. 2012;7:527–36.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Matsui TA, Sowa Y, Murata H, Takagi K, Nakanishi R, Aoki S, et al. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 2007;31:915–22.PubMed Matsui TA, Sowa Y, Murata H, Takagi K, Nakanishi R, Aoki S, et al. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 2007;31:915–22.PubMed
18.
Zurück zum Zitat Izawa H, Yamamoto H, Damdinsuren B, Ikeda K, Tsujie M, Suzuki R, et al. Effects of p21cip1/waf1 overexpression on growth, apoptosis and differentiation in human colon carcinoma cells. Int J Oncol. 2005;27:69–76.PubMed Izawa H, Yamamoto H, Damdinsuren B, Ikeda K, Tsujie M, Suzuki R, et al. Effects of p21cip1/waf1 overexpression on growth, apoptosis and differentiation in human colon carcinoma cells. Int J Oncol. 2005;27:69–76.PubMed
19.
Zurück zum Zitat Wang WZ, Zhang BY, Mei WJ, Mao JW, Li M. Effect of p21-targeted shRNA on curcumin-induced apoptosis of human hepatoma Huh7 cells. Yao Xue Xue Bao. 2009;44:1102–6.PubMed Wang WZ, Zhang BY, Mei WJ, Mao JW, Li M. Effect of p21-targeted shRNA on curcumin-induced apoptosis of human hepatoma Huh7 cells. Yao Xue Xue Bao. 2009;44:1102–6.PubMed
20.
Zurück zum Zitat Li Z, Yang L, Wang J, Shi W, Pawar RA, Liu Y, et al. beta-Actin is a useful internal control for tissue-specific gene expression studies using quantitative real-time PCR in the half-smooth tongue sole Cynoglossus semilaevis challenged with LPS or Vibrio anguillarum. Fish Shellfish Immunol. 2010;29:89–93.PubMedCrossRef Li Z, Yang L, Wang J, Shi W, Pawar RA, Liu Y, et al. beta-Actin is a useful internal control for tissue-specific gene expression studies using quantitative real-time PCR in the half-smooth tongue sole Cynoglossus semilaevis challenged with LPS or Vibrio anguillarum. Fish Shellfish Immunol. 2010;29:89–93.PubMedCrossRef
21.
Zurück zum Zitat Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J (Engl). 2004;117:936–40. Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J (Engl). 2004;117:936–40.
22.
Zurück zum Zitat Zhang CL, Liao WM, Li FB, Zeng BF, Zeng YX. Prognostic significance of p21 (WAF1) expression in osteosarcoma. Zhonghua Bing Li Xue Za Zhi. 2005;34:524–7.PubMed Zhang CL, Liao WM, Li FB, Zeng BF, Zeng YX. Prognostic significance of p21 (WAF1) expression in osteosarcoma. Zhonghua Bing Li Xue Za Zhi. 2005;34:524–7.PubMed
23.
Zurück zum Zitat Huschtscha L, Bartier W, Malmstrom A, Tattersall M. Cell death by apoptosis following anticancer drug treatment in vitro. Int J Oncol. 1995;6:585–93.PubMed Huschtscha L, Bartier W, Malmstrom A, Tattersall M. Cell death by apoptosis following anticancer drug treatment in vitro. Int J Oncol. 1995;6:585–93.PubMed
24.
Zurück zum Zitat Vinatier D, Dufour P, Subtil D. Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Eur J Obstet Gynecol Reprod Biol. 1996;67:85–102.PubMedCrossRef Vinatier D, Dufour P, Subtil D. Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Eur J Obstet Gynecol Reprod Biol. 1996;67:85–102.PubMedCrossRef
25.
26.
Zurück zum Zitat Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440–50.PubMedCrossRef Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440–50.PubMedCrossRef
27.
Zurück zum Zitat Vinatier D, Dufour P, Subtil D. Caspases: pharmacological manipulation of cell death. Eur J Obstet Gynecol Reprod Biol. 1996;67:85–102.PubMedCrossRef Vinatier D, Dufour P, Subtil D. Caspases: pharmacological manipulation of cell death. Eur J Obstet Gynecol Reprod Biol. 1996;67:85–102.PubMedCrossRef
28.
29.
Zurück zum Zitat Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002;7:321–8.PubMedCrossRef Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002;7:321–8.PubMedCrossRef
30.
Zurück zum Zitat Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol Lett. 2004;149:19–23.PubMedCrossRef Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol Lett. 2004;149:19–23.PubMedCrossRef
31.
Zurück zum Zitat Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic Bcl-2 family members. Biochem Biophys Res Commun. 2003;304:437–44.PubMedCrossRef Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic Bcl-2 family members. Biochem Biophys Res Commun. 2003;304:437–44.PubMedCrossRef
32.
Zurück zum Zitat Meeran SM, Katiyar SK. Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdki-Cdk-cyclin cascade, and caspase-3 activation via loss of mitochondrial membrane potential. Exp Dermatol. 2007;16:405–15.PubMedCrossRef Meeran SM, Katiyar SK. Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdki-Cdk-cyclin cascade, and caspase-3 activation via loss of mitochondrial membrane potential. Exp Dermatol. 2007;16:405–15.PubMedCrossRef
Metadaten
Titel
p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade
verfasst von
Yong Ding
Yucai Wang
Jun Chen
Yunsheng Hu
Zhuo Cao
Pengcheng Ren
Yong Zhang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1404-9

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.